Search results
Lightspeed Commerce (LSPD) Q4 2024 Earnings Call Transcript
Motley Fool via Yahoo Finance· 34 minutes agoAs you are well aware, I've recently returned as Lightspeed's CEO. I'm excited and energized to be...
Long Dismissed, Chronic Lyme Is Finally in the Spotlight
Time via AOL· 4 hours ago-literate" doctors, but federal health officials caution that they may not be reliable since they...
Health Care Roundup: Market Talk
The Wall Street Journal· 54 minutes agoIonis down 4.9% to $37.30. (colin.kellaher@wsj.com) 0458 ET – Roche’s phase 1 weight loss efficacy results for its injectable dual GLP-1/GLP...
Bitcoin encounters $60k resistance amid market uncertainty
CryptoNewsZ.com· 1 day agoBitcoin’s consolidation phase is not a new phenomenon. If anything, it is giving the market a sense...
Lightspeed Commerce stock surges as Dax Dasilva reappointed CEO
Yahoo Finance Canada· 3 hours ago"What this phase entails is really aligned with shareholders. It's about balancing growth... and as...
Earnings call: Lumos Pharma gears up for Phase 3 trial of LUM-201 By Investing.com
Investing.com· 1 day agoLumos Pharma (NASDAQ:LUMO), a biopharmaceutical company, detailed their progression towards a Phase...
Q1 2024 Panbela Therapeutics Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 11 hours agoI will start by discussing our clinical development program, recent achievements, and upcoming milestones. Then Sue will review our financial results before we open up the call for Q&A. Let ...
Earnings call: Zealand Pharma reports solid Q1 results, advances in obesity treatment
Investing.com· 18 hours agoCEO Adam Steensberg highlighted the company's satisfaction with its financial performance in the...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 2 hours agoKey Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal Cancer Patients Fully Enrolled NUC-7738 plus Pembrolizumab Demonstrated Encouraging Anti-Cancer Activity in Several Patients
Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic...
WFRV 5 Green Bay· 11 hours agoIonis Pharmaceuticals, Inc. (Nasdaq: IONS) and Biogen Inc. (Nasdaq: BIIB) announced the decision to terminate development of BIIB105 (ION541) an investigational antisense oligonucleotide (ASO ...
